Access to New Regimens to Patients Seeking Care in Private/Other Sectors

To expand access to the Programmatic Management of Drug-resistant TB (PMDT) services, including new regimens and new drugs like Bedaquiline, Delamanid for patients seeking care in the private sector, the following mechanisms are applicable:

• Private providers/ institutions can provide PMDT services including new regimens. Such interested and potential private providers/ institutions need to fulfil the requirements to serve as a Drug-resistant-TB Centre (DR-TBC) as per the partnership guidance of the National TB Elimination Programme (NTEP).
• For providers not in a position to fulfil the requirements of the DR-TBC, their patients can still be provided access to PMDT services, including new regimens. Such private healthcare providers can approach the concerned District TB Officer (DTO) for linkage with the concerned Nodal/ District Drug-resistant TB Centre (N/DDR-TBC) for access to DR-TB treatment as per guidelines.
• For assessing eligibility for specific regimens, all relevant medical records and reports of the patient need to be shared with the N/DDR-TBC to facilitate a decision on the regimen design that would suit the patient’s condition.
• For continuation of treatment, the private provider can continue to be the treatment supporter and monitor the patient in close coordination with the N/DDR-TBC.
• The monthly drug supply and follow-up investigations need to be undertaken as per the NTEP guidelines.

Resources

• Guidelines for Programmatic Management of Drug-resistant TB in India, 2021.

Kindly provide your valuable feedback on the page to the link provided HERE